




The Arthur and Sonia Labatt
Brain Tumour Research Centre

SickKids®



"Overcoming the adaptive response of tumors to hypoxia by targeting HIF-1 induced Carbonic Anhydrase IX/XI"



BTRC INVITED SPEAKER

Shoukat Dedhar PhD, FRSC

Professor, Department of Biochemistry and Molecular Biology, UBC
Distinguished Scientist, Department of Integrative Oncology, BC Cancer

PGCRL AUDITORIUM
3rd FLOOR, PGCRL
686 BAY STREET, TORONTO, ON

Thursday, October 31st, 2019
4:00 - 5:00PM

Hosted by Dr. James Rutka

Dr. Dedhar's work involves establishing novel mouse models of cancer metastasis, leading to significant insights into the roles of tumour microenvironment and hypoxic stress as driving forces for metastatic potential. He has identified Carbonic Anhydrase IX (CAIX) as a therapeutic target in aggressive forms of breast cancer, glioblastoma and pancreatic cancer. He has pioneered the development of a new inhibitor of CAIX, which has completed a Phase 1 clinical trial and is currently being evaluated in Phase II clinical trials. Dr. Dedhar is co-founder of SignalChem Lifesciences Corp (SLC), author of over 220 peer-reviewed papers and review articles, and an inventor on 24 patents.